Nykode Therapeutics (Vaccibody) småprat (NYKD)

[TekBot]

Nykode Therapeutics ASA – Key Information Regarding Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 25 October 2023
…

Vis børsmeldingen

Reference is made to the stock exchange notice published by Nykode Therapeutics ASA (“Nykode” or the “Company”, ticker code “NYKD“) regarding the successful placing of a private placement of new shares in the Company (the “Private Placement“) and the announcement included therein of the intention to launch a subsequent offering of shares directed towards shareholders in the Company as of 25 October 2023, as registered in VPS on 26 October 2023, who (i) were not allocated Offer Shares in the Private Placement, and (ii) are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action (the “Subsequent Offering”).

Please see below for key information regarding the Subsequent Offering:

Date of announcement of terms: 25 October 2023
Last trading day including right to receive subscription rights: 24 October 2023
First trading day excluding right to receive subscription rights: 25 October 2023
Record date: 26 October 2023
Maximum number of new shares: 5,000,000
Subscription price: NOK 17.10
Will the subscription rights be listed: No

For further information, please contact:

Harald Gurvin, CFO
Tel: +47 975 20 363, Email: hgurvin@nykode.com

IMPORTANT NOTICE
This announcement is not for publication or distribution in, directly or indirectly, Australia, Canada, Japan, Hong Kong, South Africa or the United States or any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

The Offer Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or transferred, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Offer Shares are being offered and sold (i) inside the United States to persons reasonably believe to be “qualified institutional buyers” as defined in Rule 144A of the U.S. Securities Act and (ii) outside the United States in accordance with Regulation S under the U.S. Securities Act.

In any EEA Member State, this announcement is only addressed to and is only directed at qualified investors in that Member State within the meaning of Article 2(e) of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (together with any applicable implementing measures in any Member State).

In the United Kingdom, this announcement is only addressed to and is only directed at persons who are qualified investors who are “qualified investors” within the meaning of Article 2(e) of the UK version of Regulation (EU) 2017/1129 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 and who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

The Managers are acting exclusively for the Company in connection with the Private Placement and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement or any transaction or arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein and each of them expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement.

Kilde

[TekBot]

Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 25 October 2023
…

Vis børsmeldingen

Reference is made to the stock exchange notice published by Nykode Therapeutics ASA (“Nykode” or the “Company”, ticker code “NYKD“) regarding the successful placing of a private placement of new shares in the Company (the “Private Placement“).

Please see the attached forms for information regarding share lending by closely related parties of a primary insider in connection with the Private Placement.

For further information, please contact:

Harald Gurvin, CFO
Tel: +47 975 20 363, Email: hgurvin@nykode.com

IMPORTANT NOTICE
This announcement is not for publication or distribution in, directly or indirectly, Australia, Canada, Japan, Hong Kong, South Africa or the United States or any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such jurisdiction.

The Offer Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or with any securities regulatory authority of any state or other jurisdiction of the United States and may not be offered, sold or transferred, directly or indirectly, in or into the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. The Offer Shares are being offered and sold (i) inside the United States to persons reasonably believe to be “qualified institutional buyers” as defined in Rule 144A of the U.S. Securities Act and (ii) outside the United States in accordance with Regulation S under the U.S. Securities Act.

In any EEA Member State, this announcement is only addressed to and is only directed at qualified investors in that Member State within the meaning of Article 2(e) of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression “Prospectus Regulation” means Regulation (EU) 2017/1129 (together with any applicable implementing measures in any Member State).

In the United Kingdom, this announcement is only addressed to and is only directed at persons who are qualified investors who are “qualified investors” within the meaning of Article 2(e) of the UK version of Regulation (EU) 2017/1129 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 and who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the “Order”) or (ii) are persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as “Relevant Persons”). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

The Managers are acting exclusively for the Company in connection with the Private Placement and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Private Placement or any transaction or arrangement referred to in this announcement.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intends”, “may”, “should”, “will” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein and each of them expressly disclaims any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement.

Kilde

[Xon]

Nykode henter en halv milliard – sikter mot Nasdaq - E24 Børs

[polygon]

Men de skal altså ikke skryte av noen navngitte store amerikanske investorer før åpning i dag?! Da fremstår denne emisjonen som særdeles merkelig . Og selvfølgelig negativ for de tusenvis av aksjonærene som ikke hadde EUR100k tilgjengelig i går og sto på ringelisten til tilretteleggerne (rep. emi er som vanlig kun symbolsk og helt meningsløs)

[Roc]

Blir spennende å se hvem som kjøpte og hensikten.

En slik cross over rettet emisjon ulike typer fond før IPO er jo smart, men slikt gjøres vel tradisjonelt før første notering.

Uansett, spennende og NASDAQ venter.

[Fornybar]

Har man emisjoner for å skryte av investorlisten eller for å hente penger til programmene sine?

De burde få skryt for å tidlig initiere i neoadjuvant setting, et område hvor vaksiner har bedre rasjonale enn i refraktær setting.

[solskimm]

@Roc

Uansett, spennende og NASDAQ venter.

Har de ikke snakket om NASDAQ i veldig mange år nå?

[polygon]

@Roc

En slik cross over rettet emisjon ulike typer fond før IPO er jo smart, men slikt gjøres vel tradisjonelt før første notering.

Da tenker du de ikke skal hente noe som helst, og bare notere seg på NASDAQ da?

[Boms]

Om kursen blir liggende over emisjonskursen skal det jo utstedes inntil 5 millioner aksjer til fortrinnsrettsemisjon for de som ikke var med på gårsdagens emisjon. Det er antagelig matematisk riktig, så hvorfor du kaller det meningsløst forstår jeg ikke. Men det er jo kjent fra før at du misliker det aller meste av hva Nykode gjør

Problemet er at disse emisjonene holder kursen nede i hele perioden.

[Roc]

Nei, hente på NASDAQ også, men vanlig å ha en cross over rettet emi før NASDAQ notering for spesialiserte fond som får en inngang lavere enn IPO (og hvor mange av disse selger ut endel etter IPO)

[TekBot]

Disclosure of shareholding

Reference is made to the stock exchange announcement published by Nykode Therapeutics ASA (the “Company”) on 24 October 2023 regarding the successful placing of a private placement of new shares (the “Private Placement”).

Datum Opportunity AS, a company controlled by Jan Haudemann-Andersen, will as a result of lending shares in connection with settlement of the Private Placement temporarily reduce its shareholding in the Company from 26,000,000 shares, equal to 8.80% of the current registered share capital of the Company, to 0 shares, thereby crossing the 5% disclosure threshold. The aggregate shareholdings of Jan Haudemann-Andersen and companies controlled by him (including Datum Opportunity AS) will temporarily be reduced from 40,689,050 shares, equal to 13.77% of the current registered share capital of the Company, to 11,139,650 shares, equal to 3.77% of the current registered share capital of the Company, thereby crossing the 10% and 5% disclosure thresholds.
…

Vis børsmeldingen

Upon re-delivery of borrowed shares following registration of the share capital increase pertaining to the Private Placement, Datum Opportunity AS will hold an unchanged total of 26,000,000 shares, equal to 8.00% of the expected new share capital of the Company, and Jan Haudemann-Andersen and companies controlled by him (including Datum Opportunity AS) will hold an unchanged aggregate of 40,689,050 shares, equal to 12.52% of the expected new share capital of the Company.

This announcement is made in accordance with Section 4-2 of the Norwegian Securities Trading Act.

Kilde

[polygon]

@Boms

5 millioner aksjer til fortrinnsrettsemisjon for de som ikke var med på gårsdagens emisjon.

Det der vet du godt hvordan fungerer. De fordelte 29,5 millioner aksjer til et fåtall investorer (som tilsammen eier sannsynligvis et mindretall av aksjene) i går. Og så skal de fordele ut 5 millioner i rep. emi. til de resterende. Da blir flertallet aksjonærer vannet ut på lavere kurs i en helt annen grad enn et lite mindretall. Så og si alle emisjoner gjennomføres jo på denne måten nå, så det er overhodet ikke noe spesifikt for Nykode. Men det vet jo du også.

[Boms]

Inntil man får tildelt tegningsretter, vet man ikke hvor skjevt dette er. Har de hatt kontakt med «alle» de store så vil jo ikke de få tildelt tegningsretter. Så inntil man får vite % i forhold til dagens beholdning - vet IKKE jeg om dette er dårlig for småaksjonærene.

EDIT: Husk styret inkl Datum, Rasmussengruppen, med fler skal ikke ha aksjer i fortrinnsrettsemisjonen og fikk heller ikke i emisjonen, så det er mange som ikke skal ha en del av de 5 mill aksjene.

Men at emisjonskursen/tidspunktet er helt krise, er jeg helt klar på.

[HebbeW]

Jeg tror et av de viktigste argumentene for utsatt listing på NQ har vært at eksisterende aksjonærer ikke har ønsket emisjon mot amerikanere og listing til så lave kurser. Tolker det som at styret har krøpet til korset, og vurdert fordeler større en ulemper alt tatt i betraktning. Så nå ser det ut til at listing på NQ skjer…

[polygon]

@Boms

Men at emisjonskursen/tidspunktet er helt krise, er jeg helt klar på.

Ja, foreløpig ser MCAP ut til å reduseres med mer enn de hentet inn.

Du tror kanskje at jeg koser meg nå @Boms , men jeg synes oppriktig det er trist at man nok en gang gir et lite mindretall flippere en gevinst på noen få øre på en bekostning av øvrige aksjonærer som er mye større.

[safin]

När får man veta vem som tecknat?

[Savepig]

Mer eller mindre helt konsekvent er det på Oslo Børs sånn at repemi lages slik at den ikke gir anledning til å kjøpe nok aksjer til å beskytte sin andel. Nå er det vel sjelden at repemi blir fylt opp desverre, men prinsippet er feil uansett.

[polygon]

Samtidig; når man har prøvd alternativet noen ganger de siste årene i denne bransjen, så har jo det også feilet spektakulært i å ivareta eksisterende aksjonærverdier. Men det igjen skyldes i stor grad den aktuelle diskusjonen om shorting og utlån av aksjer.

[Fornybar]

https://twitter.com/radforsk/status/1717090959865807019

[Boms]

Det jeg har hørt om allokeringen er i hovedsak følgende:

• En stor amerikansk spesialist tok 40 %
• topp 10 fikk allokert 70 %
• topp 11-20 fikk allokert 20 %
• cirka 70 fikk tildeling
• fokus på long-only spesialister og eksisterende aksjonærer
• styret fikk ikke tildeling

Så trolig ikke mange flippere, men det er jo selvfølgelig tradingmat at aksjen nå skal ha en reparasjonsemisjon hvor nye aksjer kommer i markedet om noen uker.